Physician profile
Robert D Johnston
NPI 1649272907
$14,672.31
in general payments reported to CMS, 2019-2025
85 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,768 · 2020: $1,652 · 2021: $3,789 · 2022: $1,909 · 2023: $2,117 · 2024: $905 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,554.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,176.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,317.96 | 2021 | |
| Amarin Pharma, INC. | $1,108.74 | 2019-2023 | |
| Glaxosmithkline, LLC. | $1,108.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,027.68 | 2019-2025 | |
| Novo Nordisk INC | $837.30 | 2019-2025 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $513.90 | 2020-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $378.10 | 2022-2025 | Caplyta |
| Pfizer INC. | $350.57 | 2019-2024 | |
| Djo, LLC | $328.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.97 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $301.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $287.72 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $248.82 | 2019-2024 | Xarelto |
| Neurocrine Biosciences, INC. | $242.64 | 2019-2025 | Ingrezza, Ongentys |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.